ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP raised its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 186,430 shares of the company’s stock after acquiring an additional 12,042 shares during the quarter. Wellington Management Group LLP owned approximately 0.26% of ORIC Pharmaceuticals worth $1,504,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ORIC. Vanguard Group Inc. lifted its position in shares of ORIC Pharmaceuticals by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 3,203,789 shares of the company’s stock worth $25,855,000 after purchasing an additional 36,478 shares during the last quarter. Geode Capital Management LLC lifted its holdings in ORIC Pharmaceuticals by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,273,513 shares of the company’s stock worth $13,056,000 after buying an additional 50,821 shares during the last quarter. Franklin Resources Inc. lifted its holdings in ORIC Pharmaceuticals by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after buying an additional 196,804 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of ORIC Pharmaceuticals by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 417,955 shares of the company’s stock worth $3,373,000 after acquiring an additional 7,726 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in shares of ORIC Pharmaceuticals by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 162,909 shares of the company’s stock valued at $1,315,000 after acquiring an additional 24,947 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

Analysts Set New Price Targets

ORIC has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Finally, Wedbush reiterated an “outperform” rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Thursday, March 20th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, ORIC Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $18.86.

ORIC Pharmaceuticals Stock Up 14.2 %

Shares of ORIC stock opened at $4.92 on Monday. ORIC Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67. The stock’s 50-day moving average price is $7.40 and its 200 day moving average price is $8.66. The stock has a market capitalization of $349.45 million, a PE ratio of -2.70 and a beta of 1.38.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.01. Analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.